Does the CSL share price fall finally make it a no-brainer buy?

Could shares in the healthcare giant really offer 22% upside right now?

| More on:
A scientist examining test results.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price has come off recent highs, falling 9% from its February peak to trade at $286.18 today
  • Meanwhile, the company appears to be gearing up to grow following a rough few years amid the pandemic
  • And plenty of brokers are also bullish, with one tipping the stock to reach $350 a share

CSL Limited (ASX: CSL) is the market's most expensive company on a share price basis, with each of its stocks setting an investor back $286.18 at the time of writing.

But it's recently come off a peak. The CSL share price has dumped around 9% since posting a 15-month high in February, topping out at $314.28.

Created with Highcharts 11.4.3CSL PriceZoom1M3M6MYTD1Y5Y10YALL1 Jan 202328 Mar 2023Zoom ▾9 Jan23 Jan6 Feb20 Feb6 Mar20 MarJan '23Jan '23Feb '23Feb '23Mar '23Mar '23www.fool.com.au

The company operates its Behring medicines business, its Vifor nephrology leg, its Seqirus influenza vaccines operation, and its plasma collection business.

And many brokers are tipping those businesses to grow amid rising demand, a productive research and development pipeline, and increasing plasma yields.

Indeed, one expert is forecasting the CSL share price to gain 22%. Though, not all are so bullish.

Could that mean the S&P/ASX 200 Index (ASX: XJO) biotechnology giant is finally a no-brainer buy? Let's take a closer look.

CSL share price hit hard by COVID-19

The CSL share price surged around 100% between 2018 and 2020. However, such growth slowed amid the onset of the pandemic.

Efforts to reduce the spread of COVID-19 saw the company's plasma collections tumble. Meanwhile, it embarked on an ultimately unsuccessful mission to create a vaccine for the virus.

It also underwent the $16 billion acquisition of Vifor, for which it completed a $6.3 billion capital raise in 2021.

Looking forward

Fortunately, things look to have bounced back for the ASX 200 company.

It posted record plasma collection last half, helping it achieve a US$1.6 billion profit. That's expected to come in at between US$2.7 billion and US$2.8 billion for the full year.

It's forecasting growth in plasma collections while its Hemgenix gene therapy product is expected to be launched in the United States shortly.

Finally, the integration of Vifor is said to be well advanced with delivery of synergies on schedule.

 Is CSL a buy right now?

 So, is CSL a no-brainer buy at its current share price?

Top broker Citi appears to think so. It has a buy rating and a $350 price target on the stock, my Fool colleague James reports. Citi tips the company's growth to be born from rising demand and a productive pipeline.

Meanwhile, Macquarie is expecting big things from the company's plasma collection yields, slapping CSL stock with an add rating and a $340 price target.

Rounding out the bulls is Morgans. It tips the stock to rise to $337.92 and has branded it with an add rating.

But not everyone is quite so hopeful.

Goldman Sachs is neutral on CSL shares, predicting that they'll rise to $314. The broker remains unsure of the company's path to margin recovery and is unconvinced of its valuation.

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Healthcare Shares

Guess which ASX 200 stock is jumping 16% on big news

Let's find out what news is getting investors excited this afternoon.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Healthcare Shares

Why is this ASX 300 stock crashing 18% today?

Investors are rushing to the exits. But why? Let's look into things.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are CSL shares at risk from the Trump tariffs?

How exposed are CSL shares to potential Trump medicinal tariffs?

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

What did CSL have to say at Macquarie's 2025 conference?

Does this business have a healthy growth outlook?

Read more »

smiling health care workers in a medical setting
Healthcare Shares

Sonic Healthcare shares are down more than 40% since 2021. Will its AI initiative be the catalyst for a turnaround?

Could AI spark a recovery for this ASX healthcare stock?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

Read more »